Conatumumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, which plays a crucial role in regulating immune responses. It is primarily investigated for its potential in cancer immunotherapy, aiming to enhance the immune system's ability to recognize and attack tumor cells. As a human IgG1 antibody, conatumumab is designed to bind specifically to PD-1, blocking its interaction with its ligands, PD-L1 and PD-L2. This blockade can lead to the activation of T-cells, promoting an anti-tumor immune response. Conatumumab has been studied in various clinical trials for different types of cancers, including non-small cell lung cancer and melanoma. Its pharmacokinetics involve a relatively long half-life, allowing for less frequent dosing compared to traditional chemotherapy. However, like other immunotherapies, it may be associated with immune-related adverse effects due to heightened immune activity. Overall, conatumumab represents a significant advancement in the field of targeted cancer therapies, reflecting the growing importance of immunotherapy in oncology.

Conatumumab

896731-82-1: Conatumumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, which plays a crucial role in regulating immune responses. It is primarily investigated for its potential in cancer immunotherapy, aiming to enhance the immune system's ability to recognize and attack tumor cells. As a human IgG1 antibody, conatumumab is designed to bind specifically to PD-1, blocking its interaction with its ligands, PD-L1 and PD-L2. This blockade can lead to the activation of T-cells, promoting an anti-tumor immune response. Conatumumab has been studied in various clinical trials for different types of cancers, including non-small cell lung cancer and melanoma. Its pharmacokinetics involve a relatively long half-life, allowing for less frequent dosing compared to traditional chemotherapy. However, like other immunotherapies, it may be associated with immune-related adverse effects due to heightened immune activity. Overall, conatumumab represents a significant advancement in the field of targeted cancer therapies, reflecting the growing importance of immunotherapy in oncology.

<p>Conatumumab (AMG 655) targets DR5 to induce apoptosis in tumors, with Kd of 1 nM (long DR5) and 0.8 nM (short DR5).</p>

<p>A fully human monoclonal agonist antibody against the extracellular domain of human TRAIL.</p>

CAS 896731-82-1

Conatumumab

Conatumumab

Ref: TM-T76787

Conatumumab

Ref: 3D-CLA1171